Arrowhead Total Current Liabilities vs Non Current Liabilities Total Analysis
ARWR Stock | USD 25.14 0.12 0.48% |
Arrowhead Pharmaceuticals financial indicator trend analysis is way more than just evaluating Arrowhead Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arrowhead Pharmaceuticals is a good investment. Please check the relationship between Arrowhead Pharmaceuticals Total Current Liabilities and its Non Current Liabilities Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.
Total Current Liabilities vs Non Current Liabilities Total
Total Current Liabilities vs Non Current Liabilities Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arrowhead Pharmaceuticals Total Current Liabilities account and Non Current Liabilities Total. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Arrowhead Pharmaceuticals' Total Current Liabilities and Non Current Liabilities Total is -0.05. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Non Current Liabilities Total in the same time period over historical financial statements of Arrowhead Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Arrowhead Pharmaceuticals' Total Current Liabilities and Non Current Liabilities Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Arrowhead Pharmaceuticals are associated (or correlated) with its Non Current Liabilities Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Liabilities Total has no effect on the direction of Total Current Liabilities i.e., Arrowhead Pharmaceuticals' Total Current Liabilities and Non Current Liabilities Total go up and down completely randomly.
Correlation Coefficient | -0.05 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Current Liabilities
Total Current Liabilities is an item on Arrowhead Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Arrowhead Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Liabilities Total
Most indicators from Arrowhead Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 05/23/2024, Enterprise Value is likely to grow to about 3.3 B, while Selling General Administrative is likely to drop slightly above 79.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 243.2M | 228.2M | 262.5M | 275.6M | Total Revenue | 243.2M | 240.7M | 276.8M | 290.7M |
Arrowhead Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Arrowhead Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arrowhead Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Other Current Liab | 13.5M | 23.8M | (5.6M) | (46.4M) | (53.4M) | (50.7M) | |
Total Current Liabilities | 40.7M | 146.5M | 74.1M | 866K | 995.9K | 946.1K | |
Total Stockholder Equity | 461.8M | 408.8M | 106.0M | 271.3M | 312.0M | 327.6M | |
Property Plant And Equipment Net | 47.0M | 66.0M | 168.6M | 335.6M | 385.9M | 405.2M | |
Net Debt | (122.4M) | (158.9M) | (26.4M) | 4.3M | 3.9M | 4.0M | |
Retained Earnings | (503.8M) | (644.7M) | (820.8M) | (1.0B) | (923.4M) | (877.3M) | |
Accounts Payable | 6.8M | 9.5M | 2.9M | 35.9M | 41.2M | 43.3M | |
Cash | 143.6M | 184.4M | 108.0M | 110.9M | 127.5M | 133.9M | |
Non Current Assets Total | 200.1M | 325.6M | 315.5M | 654.7M | 752.9M | 790.5M | |
Non Currrent Assets Other | 265.4K | 272K | 29.1M | 361.9M | 416.2M | 437.0M | |
Cash And Short Term Investments | 315.5M | 367.8M | 376.4M | 110.9M | 127.5M | 83.7M | |
Net Receivables | 327.4K | 661.4K | 845.7K | 10.3M | 1.4M | 0.0 | |
Common Stock Total Equity | 187.9K | 194.7K | 197K | 198K | 227.7K | 239.1K | |
Common Stock Shares Outstanding | 100.7M | 103.7M | 105.4M | 106.8M | 122.8M | 128.9M | |
Liabilities And Stockholders Equity | 522.5M | 710.1M | 691.9M | 765.6M | 880.4M | 924.4M | |
Inventory | 3.3M | 4.3M | 4.4M | (21.6M) | (19.5M) | (18.5M) | |
Other Current Assets | 1.8M | 2.2M | 20.2M | 7.1M | 8.1M | 8.6M | |
Other Stockholder Equity | 965.4M | 1.1B | 820.9M | 1.3B | 1.5B | 1.6B | |
Total Liab | 60.7M | 301.3M | 586.0M | 478.4M | 550.1M | 577.7M | |
Property Plant And Equipment Gross | 47.0M | 88.9M | 110.3M | 377.5M | 434.1M | 455.8M | |
Total Current Assets | 322.4M | 384.6M | 376.4M | 110.9M | 127.5M | 85.9M | |
Accumulated Other Comprehensive Income | 18.4K | (69K) | (136K) | (3.2M) | (2.9M) | (2.8M) | |
Short Term Debt | 1.1M | 2.3M | 2.8M | 10.6M | 12.1M | 12.8M | |
Common Stock | 194.7K | 197K | 106.0M | 200K | 230K | 218.5K | |
Current Deferred Revenue | 19.3M | 111.1M | 74.1M | 866K | 995.9K | 946.1K | |
Non Current Liabilities Total | 20.0M | 154.8M | 511.9M | 477.5M | 549.2M | 576.6M | |
Property Plant Equipment | 30.9M | 48.7M | 110.3M | 335.6M | 385.9M | 405.2M | |
Other Assets | 68.9M | 96.8M | 218K | 210K | 241.5K | 229.4K | |
Short Term Investments | 171.9M | 183.4M | 268.4M | 292.7M | 336.6M | 353.5M | |
Intangible Assets | 15.4M | 13.7M | 12.0M | 10.3M | 11.8M | 10.2M | |
Other Liab | 8.7M | 41.4M | 190.3M | 56.0M | 64.3M | 67.6M | |
Net Tangible Assets | 446.4M | 395.2M | 398.5M | 261.1M | 300.2M | 202.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (4.25) | Revenue Per Share 0.319 | Quarterly Revenue Growth (0.94) | Return On Assets (0.32) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.